Sensitivity to ALK-Directed Therapy in Osteosarcoma With an Acquired
ALK
Rearrangement
JCO Precis Oncol
.
2023 Sep:7:e2300287.
doi: 10.1200/PO.23.00287.
Authors
Zehra Ordulu
1
,
Peter Giunta
2
,
Wei-Ting Hung
2
3
,
Yin P Hung
4
,
Judit Simon
5
,
Florian J Fintelmann
5
,
Jochen K Lennerz
4
,
Kamila Naxerova
2
,
Gregory M Cote
6
Affiliations
1
Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL.
2
Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
3
Graduate Institute of Medical Genomics and Proteomics, College of Medicine, National Taiwan University, Taipei, Taiwan.
4
Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
5
Department of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
6
Department of Internal Medicine, Division of Hematology/Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
PMID:
38096470
PMCID:
PMC10730046
DOI:
10.1200/PO.23.00287
No abstract available
MeSH terms
Carcinoma, Non-Small-Cell Lung*
Humans
Lung Neoplasms*
Osteosarcoma* / genetics
Receptor Protein-Tyrosine Kinases / genetics
Substances
Receptor Protein-Tyrosine Kinases
Grants and funding
R37 CA225655/CA/NCI NIH HHS/United States